|
|
[Report]
ADME /TOX TECHNOLOGIES - A MARKET INSIGHT REPORT
Published: 2008/01
|
|
 |
|
|
|
Table of Contents
I. SCOPE AND METHODOLOGY
II. REPORT SYNOPSIS
- 1. ADME/Tox Technologies
- Absorption
- Distribution
- Metabolism
- Excretion
- Toxicity
- 2. Significant Methods for ADME/Tox.
- Predictive Technologies
- Other Related ADME/Tox Methods
- 3. ADME/Tox Technologies - Global Market Analysis
- Exhibit 1: ADME/Tox Technologies (2005-2012) - Global Market Analysis
(Current & Future) in US$ Billion (Graphical Representation included)
- Analysis by Technology
- In Vivo ADME/Tox - An Ever Growing Technology
- Global Market Analysis
- Exhibit 2: In Vivo ADME/Tox (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific, Canada and Rest of World in US$ Million (Graphical
Representation included)
- Exhibit 3: In Vivo ADME/Tox ( 2006, 2009 and 2012): Percentage
Breakdown of Global Market Value by Geographic Region for United
States, Europe, Asia-Pacific, Canada and Rest of World (Graphical
Representation included)
- Exhibit 4: List of Major Global In Vivo Companies
- In Vitro ADME/Tox - An Emerging Technology
- Global Market Analysis
- Exhibit 5: In Vitro ADME/Tox (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific, Canada and Rest of World in US$ Million (Graphical
Representation included)
- Exhibit 6: In Vitro ADME/Tox ( 2006, 2009 and 2012): Percentage
Breakdown of Global Market Value by Geographic Region for United
States, Europe, Asia-Pacific, Canada and Rest of World (Graphical
Representation included)
- Exhibit 7: List of Major Global In Vitro Companies
- In Silico ADME/Tox - The Fastest Growing Technology
- Global Market Analysis
- Exhibit 8: In Silico ADME/Tox (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific, Canada and Rest of World in US$ Million (Graphical
Representation included)
- Exhibit 9: In Silico ADME/Tox ( 2006, 2009 and 2012): Percentage
Breakdown of Global Market Value by Geographic Region for United
States, Europe, Asia-Pacific, Canada and Rest of World (Graphical
Representation included)
- Exhibit 10: List of Major Global In Vitro Companies
- 4. Regional Market Analysis
- North America
- Exhibit 11: ADME/Tox Technologies (2005-2012) - North American Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- Analysis by Technology
- In Vivo
- Exhibit 12: In Vivo ADME/Tox (2005-2012) - North American Market
Analysis (Current & Future) for United States and Canada in US$
Million (Graphical Representation included)
- Exhibit 13: In Vivo ADME/Tox ( 2006, 2009 and 2012): Percentage
Breakdown of North American Market Value for United States and Canada
- In Vitro
- Exhibit 14: In Vitro ADME/Tox (2005-2012) - North American Market
Analysis (Current & Future) for United States and Canada in US$
Million (Graphical Representation included)
- Exhibit 15: In Vitro ADME/Tox ( 2006, 2009 and 2012): Percentage
Breakdown of North American Market Value for United States and Canada
- In Silico
- Exhibit 16: In Silico ADME/Tox (2005-2012) - North American Market
Analysis (Current & Future) for United States and Canada in US$
Million (Graphical Representation included)
- Exhibit 17: In Silico ADME/Tox ( 2006, 2009 and 2012): Percentage
Breakdown of North American Market Value for United States and Canada
- Europe
- Exhibit 18: ADME/Tox Technologies (2005-2012) - European Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- Analysis by Technology
- In Vivo
- Exhibit 19: In Vivo ADME/Tox Technologies (2005-2012) - European
Market Analysis (Current & Future) by Geographic Region for UK,
Germany, France, Sweden, Finland, Italy and Rest of Europe in US$
Million (Graphical Representation included)
- Exhibit 20: In Vivo ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of European Market Value by Geographic Region for
UK, Germany, France, Sweden, Finland, Italy and Rest of Europe
(Graphical Representation included)
- In Vitro
- Exhibit 21: In Vitro ADME/Tox Technologies (2005-2012) - European
Market Analysis (Current & Future) by Geographic Region for UK,
Germany, France, Sweden, Finland, Italy and Rest of Europe in US$
Million (Graphical Representation included)
- Exhibit 22: In Vitro ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of European Market Value by Geographic Region for
UK, Germany, France, Sweden, Finland, Italy and Rest of Europe
(Graphical Representation included)
- In Silico
- Exhibit 23: In Silico ADME/Tox Technologies (2005-2012) - European
Market Analysis (Current & Future) by Geographic Region for UK,
Germany, France, Sweden, Finland, Italy and Rest of Europe in US$
Million (Graphical Representation included)
- Exhibit 24: In Silico ADME/Tox Technologies ( 2006, 2009 and
2012): Percentage Breakdown of European Market Value by Geographic
Region for UK, Germany, France, Sweden, Finland, Italy and Rest of
Europe (Graphical Representation included)
- Asia-Pacific
- Exhibit 25: ADME/Tox Technologies (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- Analysis by Technology
- In Vivo
- Exhibit 26: In Vivo ADME/Tox (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Geographic Region for Japan, China,
India, Australia, and Rest of Asia-Pacific in US$ Million (Graphical
Representation included)
- Exhibit 27: In Vivo ADME/Tox Technologies ( 2006, 2009 and
2012): Percentage Breakdown of Asia-Pacific Market Value by
Geographic Region for Japan, China, India, Australia and Rest of
Asia-Pacific (Graphical Representation included)
- In Vitro
- Exhibit 28: In Vitro ADME/Tox (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Geographic Region for Japan, China,
India, Australia, and Rest of Asia-Pacific in US$ Million (Graphical
Representation included)
- Exhibit 29: In Vitro ADME/Tox Technologies ( 2006, 2009 and
2012): Percentage Breakdown of Asia-Pacific Market Value by
Geographic Region for Japan, China, India, Australia and Rest of
Asia-Pacific (Graphical Representation included)
- In Silico
- Exhibit 30: In Silico ADME/Tox (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Geographic Region for Japan, China,
India, Australia, and Rest of Asia-Pacific in US$ Million (Graphical
Representation included)
- Exhibit 31: In Silico ADME/Tox Technologies ( 2006, 2009 and
2012): Percentage Breakdown of Asia-Pacific Market Value by
Geographic Region for Japan, China, India, Australia and Rest of
Asia-Pacific (Graphical Representation included)
- Rest of World
- Exhibit 32: ADME/Tox Technologies (2005-2012) - Rest of World Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
III. PRODUCT/TECHNOLOGY RESEARCH
- 1. ADME/Tox - The Basics
- Absorption
- Distribution
- Metabolism
- Excretion
- Toxicity
- Global ADME/TOX Market
- Exhibit 33: Global Market for ADME/Tox Technologies: Geographic
Regions (Europe, Canada, United States, Asia-Pacific, and Rest of World)
Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation
included)
- Factors Determined by ADME/TOX
- ADME/TOX Properties - Determined by
- The Increasing Need to Predict ADME/TOX Profiles
- Biological Assay Systems for the Evaluation of Cytochrome P450 Enzyme
Isoforms
- Technologies for Lead Generation
- CommonTechnologies for Lead Generation Include
- Technologies for Preclinical Development of Drug Candidates
- Preclinical ADME/TOX Evaluation Tools
- Preclinical ADME/TOX Tools are Generally Validated for
- 2. ADME/Tox Methods
- High Throughput Screening
- Global HTS Market
- Exhibit 34: Global Market for HTS: Geographic Regions (Asia-Pacific,
Europe, Canada, United States, and Rest of World) Ranked by Projected
CAGR for 2005 through 2012 (Graphical Representation included)
- Screening Technologies
- The Various Types of Screening Technologies
- Primary Screening
- Secondary Screening
- Biochemical Assays
- Cell based Assays
- High Content Screening
- Predictive Technologies
- Exhibit 35: Global Market for ADME/Tox Technologies: Predictive
Technologies (In Silico, In Vitro and In Vivo) Ranked by Projected
CAGR for 2005 through 2012 (Graphical Representation included)
- In Vivo ADMET
- Global In Vivo ADMET Market
- Exhibit 36: Global Market for In Vivo ADME/TOX Technologies:
Geographic Regions, (Canada , Europe, US, Asia-Pacific and Rest of
World Ranked by Projected CAGR for 2005 through 2012 (Graphical
Representation included)
- Importance of In Vivo Tests
- Exhibit 37: In Vivo ADME/Tox Methods
- Modern In Vivo ADME/Tox Models
- Zebrafish
- Rodent Models
- Drosophila
- C.elegans
- Conventional In Vivo ADME/TOX Models
- Radiolabels
- Cassette Dosing
- Semi Simultaneous Dosing
- Why do we Need Animals for Trials?
- In Vitro ADMET
- Global In Vitro ADMET Market
- Exhibit 38: Global Market for In Vitro ADME/Tox Technologies:
Geographic Regions (Canada , Europe, Asia-Pacific, US and Rest of
World Ranked by Projected CAGR for 2005 through 2012 (Graphical
Representation included)
- In Vitro Assays
- Veterinary In Vitro Testing
- Exhibit 39: Veterinary In Vitro Testing Technologies (2005-2012) -
Global Value Analysis in US$ Million
- In Vitro Applications for Drug Discovery and Development
- Human and Animal Metabolism
- Permeation Studies
- Other ADME Services
- Exhibit 40: In Vitro ADME/TOX Methods
- Examples of Human In Vitro ADME/TOX Assays Include
- In Silico ADMET
- Global In Silico ADMET Market
- Exhibit 41: Global In Silico ADME/TOX Market: Geographic Regions
(Europe,US,Asia- Pacific, Canada, and Rest of World Ranked by CAGR for
2005 through 2012 (Graphical Representation included)
- In Silico Applications along Preclinical Stages
- Target Identification
- Lead Optimization
- Target Validation
- ADME/TOX Analysis
- In Silico Predictive Models
- Broad Segmentation of In Silico technology
- The Market For In Silico by Segment
- Exhibit 42: In Silico ADME/Tox (2005-2012) - Global Market
Analysis by Segment for Organ and Tissue Cells, Cellular Networks, and
Whole Cells in US$ Million (Graphical Representation included)
- Exhibit 43: In Silico ADME/TOX ( 2006, 2009 and 2012): Percentage
Breakdown of Global Market Value by Segment for Organ and Tissue
Cells, Cellular Networks, and Whole Cells (Graphical Representation
included)
- Applications of In Silico Models in Drug Discovery Process
- Potential Applications of In Silico Technology
- Prediction of In Silico Profiles by Metabolic behavior
- The Market for In Silico Technologies
- The Prospects
- The Constraints
- 3. Toxicity
- Preclinical Toxicology
- Predictive Toxicology
- Determining Factors for Effective Predictive Toxicology in Preclinical
Stage
- Remedial Measures
- Exhibit 44: Common Types of Toxicity Targeted for ADME/TOX
Predictive Techniques
- Computational Toxicology
- In Vitro Toxicology
- In Vitro Toxicology - Liver Cell Models
- Tissue Culture Systems Used in In Vitro Toxicology
- In Vitro Toxicology Applications
- Genomics in Toxicity Testing
- Examining Neurotoxicity
- Exhibit 45: Common Approved In Vitro and In Vivo Procedures
- Alternatives for Animals in Toxicity Testing
- Exhibit 46: The Common Animals Used for ADME and Toxicity Testing
(Graphical Representation included)
- Exhibit 47: Non-animal Methods being Considered for Validation
- 4. ADME/TOX - An Essence of Pharmaceutical Industry
- The Reasons for the Decline in Success Rates
- The Process of Drug Discovery
- Target Identification
- Target Validation
- Lead Identification
- Lead Optimization
- Clinical Trials
- Phase I
- Phase II
- Phase III
- Exhibit 48: The Critical Path for a Drug to Enter Clinical Trials
- Exhibit 49: Global Expenditure on Development and Approval of New
Drugs: 2005 - 2012 (In US$ Million) (Graphical Representation included)
- Exhibit 50: Estimated Time Required for Development of Drugs by
Primary Indication (In Years) (Graphical Representation included)
- Exhibit 51: Global R & D Expenditure of Every New Chemical Entity
(NEC) Launched: 2005 to 2012 (In US$ Million) (Graphical
Representation included)
- Exhibit 52: Drug Developmental Costs by Phase (Pre-approval)
(Graphical Representation included)
- 5. ADME/TOX in Drug Discovery Process
- Stages in Preclinical Studies
- The Factors Influencing Drug Approval Rates
- Exhibit 53: New Drug Attrition Rate: Percentage Breakdown of Factors
Contributing to New Drug Failure for Inaptancy of Bioavailability,
Toxicity, Commercial Drawbacks and Other (Graphical Representation
included)
- Exhibit 54: Attrition of Compounds from Discovery to Launch Phase of a
Drug (In number of compounds) (Graphical Representation included)
- Overlapping of Predictive ADME/TOX Technologies
- Applications by Technology
- Exhibit 55: Overlapping of Predictive ADME/TOX Technology Applications
Across Various Stages of Drug Discovery (Graphical Representation included)
- 6. ADME/TOX and Drug Discovery Technologies
- Pharmacogenomics
- Pharmacokinetics
- A - Category
- D - Category
- M - Category
- E - Category
- Exhibit 56: Classification of Protein Targets by Category
- Proteomics
- Bioinformatics
- 7. Challenges Facing the ADME/TOX Industry
IV. MARKET DYNAMICS
- 1. Global Market Analysis
- Exhibit 57: ADME/Tox Technologies (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific, Canada and Rest of World in US$ Million (Graphical
Representation included)
- Exhibit 58: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
Breakdown of Global Market Value by Geographic Region for United States,
Europe, Asia-Pacific, Canada and Rest of World (Graphical Representation
included)
- Global Markets in Related Technologies
- Laboratory Information Management Systems
- Global Market for LIMS
- Exhibit 59: Laboratory Information Management System (LIMS)
(2005-2012) - Global Market Analysis (Current & Future) in US$ Million
(Graphical Representation included)
- High Throughput Screening
- Global HTS Market
- Exhibit 60: High Throughput Screening (HTS) (2005-2012) - Global
Market Analysis (Current & Future) in US$ Billion (Graphical
Representation included)
- HTS Analysis by Geographic Region
- Exhibit 61: High Throughput Screening (HTS) (2005-2012) - Global
Market Analysis (Current & Future) by Geographic Region for United
States, Europe, Asia-Pacific, Canada and Rest of World in US$ Million
(Graphical Representation included)
- Exhibit 62: High Throughput Screening (HTS) ( 2006, 2009 and
2012): Percentage Breakdown of Global Market Value by Geographic
Region for United States, Europe, Asia-Pacific, Canada and Rest of
World (Graphical Representation included)
- Global Market for HTS Products
- Exhibit 63: HTS Products (2005-2012) - Global Market Analysis
(Current & Future) in US$ Million (Graphical Representation included)
- Global Market for Re-Screening of Hits
- Exhibit 64: Re-Screening of Hits (2005-2012) - Global Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- Global Market for HTS Services and Consumables
- Exhibit 65: HTS Services and Consumables (2005-2012) - Global
Market Analysis (Current & Future) in US$ Billion (Graphical
Representation included)
- Global Market for HTS Services and Call Based Consumables
- Exhibit 66: HTS Services and Cell Based Consumables (2005-2012) -
Global Market Analysis (Current & Future) in US$ Billion (Graphical
Representation included)
- Global Spending on HTS for Lead Discovery
- Exhibit 67: High Throughput Screening (HTS) (2005-2012) - Analysis
of Global Spending for Lead Discovery by Geographic Region for United
States, Europe, and Rest of World in US$ Billion (Graphical
Representation included)
- Exhibit 68: High Throughput Screening (HTS) ( 2006, 2009 and
2012): Percentage Breakdown of Global Value of Spending for Lead
Discovery by Geographic Region for United States, Europe,
Asia-Pacific, Canada and Rest of World (Graphical Representation
included)
- Cell Based Assays
- Global Market for Cell Based Assays
- Exhibit 69: Cell-Based Assays (2005-2012) - Global Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- Cell Based Assay Analysis by Geographic Region
- Exhibit 70: Cell-Based Assays (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for United States, Europe,
Asia-Pacific, Canada and Rest of World in US$ Million (Graphical
Representation included)
- Exhibit 71: Cell-Based Assays ( 2006, 2009 and 2012): Percentage
Breakdown of Global Market Analysis (Current & Future) by Geographic
Region for United States, Europe, Asia-Pacific, Canada and Rest of
World (Graphical Representation included)
- Global Pharmaceutical Cell Based Screening Market
- Exhibit 72: Pharmaceutical Cell-Based Screening (2005-2012) -
Global Market Analysis (Current & Future) in US$ Billion (Graphical
Representation included)
- Global Drug Discovery Market
- Global Drug Discovery Expenditure
- Exhibit 73: Drug Discovery (2005-2012) - Global Expenditure in
US$ Billion (Graphical Representation included)
- Global Biotech Industry at a Glance
- Major Research Areas in Biotechnology
- Exhibit 74: Global Biotechnology Industry (2005): Percentage
Breakdown of Major Research Areas (Graphical Representation included)
- 2. The Need of the Hour
- 3. ADME/Tox - The Emerging Trends
- 4. Major Companies in ADME/Tox Industry
- Accelrys, Inc. (USA)
- ADMET Technologies (USA)
- Advanced Chemistry Development, Inc. (ACD/Labs) (Canada)
- Agilent Technologies, Inc. (USA)
- AMRI Hungary, Inc. (Hungary)
- Applied Biosystems Group (USA)
- Argenta Discovery Ltd. (UK)
- Aureus Pharma (France)
- Bayer Technology Services GmbH (Germany)
- BD Biosciences (USA)
- Biacore International AB (Sweden)
- BioFocus DPI (UK)
- Bio-Rad Laboratories, Inc. (USA)
- Bridge Pharmaceuticals (USA)
- Caliper Life Sciences, Inc. (USA)
- Cellomics, Inc. (USA)
- Celsis International plc (UK)
- Cerep SA (France)
- Charles River Laboratories, Inc. (USA)
- ChemSilico LLC (The) (USA)
- Chenomx, Inc. (Canada)
- CompuDrug International, Inc. (USA)
- Cyprotex plc (UK)
- Gene Logic, Inc. (USA)
- Iconix Pharmaceuticals, Inc. (USA)
- ID Business Solutions Ltd. (UK)
- Invitrogen, Inc. (USA)
- Kendle International, Inc. (USA)
- Kibron, Inc. (Finland)
- LHASA Ltd. (UK)
- MDL Information Systems (USA)
- Millipore Corporation (USA)
- Molecular Discovery Ltd. (UK)
- MultiCASE, Inc. (USA)
- Noray Bioinformatics S.L. (Spain)
- Perkin Elmer, Inc. (USA)
- Pharma Algorithms (Canada)
- Promega Corporation (USA)
- Qualyst, Inc. (USA)
- Ranbaxy Laboratories Ltd. (India)
- Schrodinger LLC (USA)
- Simulations Plus, Inc. (USA)
- Sirius Analytical Instruments Ltd. (UK)
- Stem Cell Innovations, Inc. (USA)
- Strand Life Sciences (India)
- Sygnis Pharm AG (Germany)
- Tecan AG (Switzerland)
- Thermo Fisher Scientific, Inc. (USA)
- Tripos, Inc. (USA)
- Waters Corporation (USA)
- Xceleron Ltd. (UK)
- 5. Major Activities In ADME/Tox Industry
- Gene Logic Divests Genomics Assets and Changes Corporate Identity
- ChemDiv Extends Partnership Agreement with NMSI
- Medivir Gives New Structure to Drug Discovery
- Entelos, Inc. Agrees to Acquire Iconix Biosciences, Inc
- Cerep Sells Hesperion AG Business to Averion International
- BioFocus DPI Brings Further Advancement to ADME Optimization Services
- Symyx Technologies Closes Acquisition of MDL Information Systems
- Simulations Plus Signs Research Agreement with Enslein
- Gene Logic Enters into Alliance with FDA
- Gene Logic Enters into Alliance with Solvay Pharmaceuticals to Trace New
Development Channels for Multiple Clinical Drug Candidates
- Amgen Concludes Ilypsa Acquisition
- Waters Corporation Signs Collaborative Agreement with Umetrics AB
- TetraQ gains GLP status for the ADME laboratory from NATA
- Waters Corporation to Collaborate with Dotmatics Limited
- Aureus Pharma Partners with MDL® Isentris® Alliance
- Galapagos Enters into Alliance with AstraZeneca for Novel Drug Discovery
- Galapagos Collaborates with Ono Pharmaceutical
- Lexicon Genetics Adopts New Corporate Identity
- Avista Capital Acquires BioReliance Corporation
- VASTox plc Acquires Dextra Laboratories and DanioLabs
- Takeda Pharmaceutical Acquires Paradigm Therapeutics Limited
- MDS Acquires Entire Stake in MDC
- Thermo Fisher Scientific Acquires Cohesive Technologies
- Qualyst and InterMune in B-CLEAR® Technology Licensing Deal
- LION bioscience Adopts New Identity
- PerkinElmer Acquires Euroscreen Products and Evotec Technologies
- Galapagos Acquires Inpharmatica
- Invitrogen Acquires Sentigen
- Affymetrix and Iconix Launch ToxFXTM
- MPI Research Takes Over Exygen Research
- Accium BioSciences Forms Strategic Alliance with CMIC
- Pharma Algorithms Unveils ADME Boxes version 3.5
- Covance Licenses B-CLEAR® From Qualyst, Inc.
- Northwest Kinetics, Inc. Acquired by Charles River Laboratories
- Strand Life Sciences forms Partnership with BioIT Alliance
- Agilent Signs Agreement with Mass Consortium
- Calando Picks Agilent for siRNA production
- Origenis Becomes First Customer to Aureus Pharma' s AurWEB
- Invitrogen Pockets TEF Product Lines
- Odyssey Forms Alliance with Pfizer
- Agilent Bags CGH Microarray License from Abbott
- Celsis Acquires In Vitro Technologies
- Cohesive Collaborates with Mayo Clinic
- CHDI Partners with Evotec
- Hesperion Takes Over Touchstone
- Iconix Inks Services Agreement with Merck
- BioDynamics Partners with Noray
- DAC Inks Agreement with Evotec
- Millipore acquires Serologicals
- Aureus Pharma Issues License on AurSCOPE
- Aureus Pharma Issues License on hERG and AurSCOPE ADME
- Boehringer Bags MetaCore License from GeneGo
- NovaScreen Bags HTS Contract from Wyeth
- Ingenuity Signs Integration Agreement with Agilent
- Bio-Rad Collaborates with Infometrix
- BioWisdom Takes Over Bioinformatics Business of LION
- BGM Forms Collaboration with Mitsubishi Pharma
- Iconix Broadens Toxicogenomics Gene Expression Database
- Qualyst and Oxford Biomedical Research in License Agreement for
ACCURATE™
- PerkinElmer signs xMap licensing agreement with Luminex
- Genospectra Merges with Panomics
- Affymetrix Enters into Collaboration with Iconix
- Varian Bags FTMS Technology
- Evotec Bags HCS Patent License from Cellomics
- Tripos and InforSense enter into Informatics Alliance
- Xceleron Inks Collaborative Agreement with Servier
- Iconix Forms Collaboration with Eli Lilly
- Strand Life Sciences and Elan Enter into Collaboration
- TetraQ forms Alliance with Ground Zero Pharmaceuticals
- BGM Conducts Joint Toxicity Study with FDA
- Qualyst and SC BioSciences Announce B-CLEAR® Marketing alliance in
Japan
- Simulations Plus Acquires Sage Informatics
- Xceleron Enters into Preferred Supply Agreement with GSK
- Bio-Rad Enters into Collaboration with Equbits and Aureus Pharma
- 6. Major Product Introductions/Developments in ADME/Tox Industry
- Pharma Algorithms Releases New ADME Boxes Version 4.0
- Simulations Plus Releases New Important Upgrade of ClassPharmer™
Software
- Applied Biosystems and Sciex Jointly Launch the New Cliquid™ Drug
Screen and Quant Software for Application in Routine Forensic Toxicology
- BioReliance Introduces Novel Genotoxicity Screening Service
- Caliper Life Sciences Introduces CDAS for Offering Complete Drug
Discovery and Development Services
- Simulations Plus Introduces New DNA Mutation Predictor
- Simulations Plus Launches ADMET Predictor™ Version 2.3
- Pharma Algorithms Announces ToxBox Version 2.0
- Aureus Pharma Introduces New Tool to Identify Risks of Drug-Drug
Interactions
- DTEx™ - New technology for Gene Expression Profiling for Drugs
- Strand Introduces New Platform for In Silico Lead Optimization
- NMS Introduces the New Brand Accelera
- Simulations Plus Introduces New Predictive Models Expected to Improve
Anti-HIV Activity Discovery Capability
- InterMune Employs B-CLEAR® Technology for Drug Discovery Applications
- Quantum Pharmaceuticals Releases an Innovative Platform
- Agilent Launches Oligo array based Chip-on-chip Microarrays
- Invitrogen Launches Advanced Transfection Reagents
- Thermo Electron (Thermo Fisher Scientific) Introduces Updates to Darwin
LIMS™
- Accelrys Introduces Discovery Studio® 1.6
- Bio-Rad releases version 7.5 of its KnowItAll Informatics System
- Applied Biosystems and GeneGo Enter into Collaboration for Tissue Gene
Expression
- Aureus Pharma Unveils AurSCOPE® Kinase
- Bionas Launches In Vitro Profiling Device
- Caliper Unveils Xenogen
- Genetix Produces CloneFill
- Genetix Introduces Cell Dispense
- Millipore Introduces 96-Well Millicell Plate
- Peakdale Launches Peakfinder® Kinase Arrays
- Applied Biosystems Adds a Million Genotyping Assays to Its TaqMan®
Collection
- Invitrogen Signs Agreement to Add ClonepixFL Technology of Genetix to
Process Development Services
- Aureus Pharma Issues License on AurSCOPE
- Aureus Pharma Issues License on hERG and AurSCOPE ADME
- Simulations Plus Launches Latest Versions of ADMET Software
- Schrödinger Updates Schrödinger Suite 2006
- Thermo Electron (Thermo Fisher Scientific) Launches Galileo LIMS v 3.2
- Bio-Rad Incorporates MolSAR™ Technology into KnowItAll
- Malvern Instruments' Zetasizer Nano S Selected For Drug Delivery
Research Use
- Inpharmatica Expands Admensa Interactive™ Drug Discovery Tools
- Peakdale Announces Completion of Peakexplorer™ GPCR Collection
- SSi Robotic' s FLASH™ System Selected by Invitrogen
- Gene Logic Introduces ASCENTA® System 2.0
- ReNeuron Develops Human Hepatocyte Cell Lines
- Spotfire Launches Microarray Application
- GeneGo Combines MetaDrug™ and Accelrys' Accord Technology
- Bioreason Unveils ClassPharmer Suite
- GE Healthcare Releases ADME Rat Microarray
- Millipore and Caliper Develop HT Protocols
- Waters Introduces Waters® MassTrak
- Bio-Rad Laboratories Inc., Introduces ADMET Databases
- Molecular Devices Corporation Launches Assay Kits for Early ADME
Screening
- Thermo Electron (Thermo Fisher Scientific) Introduces LeadStream
ADME/Tox Solution™
- Beckman Coulter Inc., Launches Biomek FX ADMETox Workstation
- 7. Regional Market Analysis
- A. The United States
- US Market Analysis
- Exhibit 75: ADME/Tox Technologies (2005-2012) - United States Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- Exhibit 76: List of Major Companies in The United States
- Analysis by Technology
- Exhibit 77: ADME/Tox Technologies (2005-2012) - United States
Market Analysis (Current & Future) by Predictive Technology for In
Vivo, In Vitro and In Silico in US$ Million (Graphical Representation
included)
- Exhibit 78: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of United States Market Value by Predictive
Technology for In Vivo, In Vitro and In Silico (Graphical
Representation included)
- Market for Related Technologies in The United States
- US Market for HTS
- Exhibit 79: High Throughput Screening (HTS) (2005-2012) - United
States Market Analysis (Current & Future) in US$ Billion (Graphical
Representation included)
- US Spending on HTS for Lead Discovery
- Exhibit 80: High Throughput Screening (HTS) (2005-2012) - United
States Spending for Lead Discovery in US$ Million (Graphical
Representation included)
- US Market for Cell Based Assays
- Exhibit 81: Cell-Based Assay (2005-2012) - United States Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- US Market for Pharma Contract Research
- Exhibit 82: Pharmaceutical Contract Research (2005-2012) - United
States Market Analysis (Current & Future) in US$ Million (Graphical
Representation included)
- Exhibit 83: Number of Drugs with Potential Approval in the United
States: 2005 - 2006 Estimates (Graphical Representation included)
- B. Canada
- Exhibit 84: ADME/Tox Technologies (2005-2012) - Canadian Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- Exhibit 85: List of Major Companies in Canada
- Analysis by Technology
- Exhibit 86: ADME/Tox Technologies (2005-2012) - Canadian Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 87: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
Breakdown of Canadian Market Value by Predictive Technology for In Vivo,
In Vitro and In Silico (Graphical Representation included)
- Market for Related Technologies in Canada
- Canadian Market for HTS
- Exhibit 88: High Throughput Screening (HTS) (2005-2012) - Canadian
Market Analysis (Current & Future) in US$ Million (Graphical
Representation included)
- Canadian Market for Cell Based Assays
- Exhibit 89: Cell-Based Assay (2005-2012) - Canadian Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- Canadian Market for Biotech R&D
- Exhibit 90: Biotechnology R&D Expenditure (2005-2012) - Canadian
Market Analysis (Current & Future) in US$ Million (Graphical
Representation included)
- C. Europe
- Exhibit 91: ADME/Tox Technologies (2005-2012) - European Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- Exhibit 92: List of Major Companies in Europe
- Analysis by Geographic Region
- Exhibit 93: ADME/Tox Technologies (2005-2012) - European Market
Analysis (Current & Future) by Geographic Region for UK, Germany,
France, Sweden, Finland, Italy and Rest of Europe in US$ Million
(Graphical Representation included)
- Exhibit 94: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
Breakdown of European Market Value by Geographic Region for UK, Germany,
France, Sweden, Finland, Italy and Rest of Europe (Graphical
Representation included)
- Analysis by Segment
- Exhibit 95: ADME/Tox Technologies (2005-2012) - European Market
Analysis (Current & Future) by Segment for Services and Technology in
US$ Million (Graphical Representation included)
- Exhibit 96: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
Breakdown of European Market Value by End-Use Sector for Services and
Technology (Graphical Representation included)
- Analysis by Technology
- Exhibit 97: ADME/Tox Technologies (2005-2012) - European Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 98: ADME/Tox Technologies ( 2006, 2009 and 2012): Percentage
Breakdown of European Market Value by Predictive Technology for In Vivo,
In Vitro and In Silico (Graphical Representation included)
- Market for Related Technologies in Europe
- European Market for HTS
- Exhibit 99: High Throughput Screening (HTS) (2005-2012) - European
Market Analysis (Current & Future) in US$ Billion (Graphical
Representation included)
- European Spending on HTS for Lead Discovery
- Exhibit 100: High Throughput Screening (HTS) (2005-2012) -
European Spending for Lead Discovery in US$ Billion (Graphical
Representation included)
- European Market for Cell Based Assays
- Exhibit 101: Cell-Based Assay (2005-2012) - European Market
Analysis (Current & Future) in US$ Million (Graphical Representation
included)
- European Market for Drug Discovery
- Exhibit 102: Drug Discovery (2005-2012) - European Market Analysis
(Current & Future) in US$ Billion (Graphical Representation included)
- European Market for Drug Discovery Outsourcing
- Exhibit 103: Drug Discovery Outsourcing (2005-2012) - European
Market Analysis (Current & Future) in US$ Billion (Graphical
Representation included)
- European Market for Nanotechnology Based Drug Discovery
- Exhibit 104: Drug Discovery Based on Nanotechnology (2005-2012) -
European Market Analysis (Current & Future) in US$ Million (Graphical
Representation included)
- European Biotechnology Market
- Exhibit 105: Biotechnology R&D Expenditure (2005-2012) - European
Market Analysis (Current & Future) in US$ Billion (Graphical
Representation included)
- European ADME/Tox Market by Country
- C1. The United Kingdom
- Major Companies in UK ADME/Tox Market
- UK Marker Analysis
- Exhibit 106: ADME/Tox Technologies (2005-2012) - UK Market Analysis
(Current & Future) by Predictive Technology for In Vivo, In Vitro and In
Silico in US$ Million (Graphical Representation included)
- Exhibit 107: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of UK Market Value by Predictive Technology for In
Vivo, In Vitro and In Silico (Graphical Representation included)
- C2. Germany
- Major Companies in German ADME/Tox Market
- German Market Analysis
- Exhibit 108: ADME/Tox Technologies (2005-2012) - German Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 109: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of German Market Value by Predictive Technology for
In Vivo, In Vitro and In Silico (Graphical Representation included)
- C3. France
- Major Companies in French ADME/Tox Market
- French Market Analysis
- Exhibit 110: ADME/Tox Technologies (2005-2012) - French Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 111: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of French Market Value by Predictive Technology for
In Vivo, In Vitro and In Silico
- C4. Finland
- Major Companies in Finnish ADME/Tox Market
- Finnish Market Analysis
- Exhibit 112: ADME/Tox Technologies (2005-2012) - Finnish Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 113: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Finnish Market Value by Predictive Technology
for In Vivo, In Vitro and In Silico
- C5. Italy
- Major Companies in Italian ADME/Tox Market
- Italian Market Analysis
- Exhibit 114: ADME/Tox Technologies (2005-2012) - Italian Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 115: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Italian Market Value by Predictive Technology
for In Vivo, In Vitro and In Silico
- C6. Sweden
- Major Company in Swedish ADME/Tox Market
- Swedish Market Analysis
- Exhibit 116: ADME/Tox Technologies (2005-2012) - Swedish Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 117: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Swedish Market Value by Predictive Technology
for In Vivo, In Vitro and In Silico
- C7. Rest of Europe
- Analysis by Geographic Region
- Exhibit 118: ADME/Tox Technologies (2005-2012) - Rest of Europe
Market Analysis (Current & Future) by Geographic Region for Switzerland,
Hungary, Belgium, Austria, Spain and Other in US$ Million (Graphical
Representation included)
- Exhibit 119: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Rest of Europe Market Value by Geographic Region
for Switzerland, Hungary, Belgium, Austria, Spain and Other
- Analysis by Technology
- Exhibit 120: ADME/Tox Technologies (2005-2012) - Rest of Europe
Market Analysis (Current & Future) by Predictive Technology for In Vivo,
In Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 121: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Rest of Europe Market Value by Predictive
Technology for In Vivo, In Vitro and In Silico
- D. Asia-Pacific
- Exhibit 122: ADME/Tox Technologies (2005-2012) - Asia-Pacific Market
Analysis in US$ Million (Graphical Representation included)
- Exhibit 123: List of Major Companies in Asia-Pacific
- Analysis by Geographic Region
- Exhibit 124: ADME/Tox Technologies (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Geographic Region for Japan, China,
India, Australia and Rest of Asia-Pacific in US$ Million (Graphical
Representation included)
- Exhibit 125: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Asia-Pacific Market Value by Geographic Region
for Japan, China, India, Australia and Rest of Asia-Pacific
- Analysis by Technology
- Exhibit 126: ADME/Tox Technologies (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 127: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Asia-Pacific Market Value by Predictive
Technology for In Vivo, In Vitro and In Silico
- Drug Discovery Scenario in Asia-Pacific
- Asia-Pacific Market for HTS
- Exhibit 128: High Throughput Screening (HTS) (2005-2012) -
Asia-Pacific Market Analysis (Current & Future) in US$ Million
(Graphical Representation included)
- Asia-Pacific Market for Drug Discovery
- Exhibit 129: Drug Discovery (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) in US$ Billion (Graphical Representation
included)
- Asia-Pacific Market for Pharma CROs
- Exhibit 130: Pharmaceutical Contract Research Organization (CROs)
(2005-2012) - Asia-Pacific Market Analysis (Current & Future) in US$
Billion (Graphical Representation included)
- Asia-Pacific ADME/Tox Market by Country
- D1. Japan
- Major Companies in Japanese ADME/Tox Market
- Japanese Market Analysis
- Exhibit 131: ADME/Tox Technologies (2005-2012) - Japanese Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 132: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Japanese Market Value by Predictive Technology
for In Vivo, In Vitro and In Silico
- D2. China
- Major Companies in Chinese ADME/Tox Market
- Chinese Market Analysis
- Exhibit 133: ADME/Tox Technologies (2005-2012) - Chinese Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 134: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Chinese Market Value by Predictive Technology
for In Vivo, In Vitro and In Silico
- D3. India
- Major Companies in Indian ADME/Tox Market
- Indian Market Analysis
- Exhibit 135: ADME/Tox Technologies (2005-2012) - Indian Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 136: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Indian Market Value by Predictive Technology for
In Vivo, In Vitro and In Silico
- D4. Australia
- Australian Market Analysis
- Exhibit 137: ADME/Tox Technologies (2005-2012) - Australian Market
Analysis (Current & Future) by Predictive Technology for In Vivo, In
Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 138: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Australian Market Value by Predictive Technology
for In Vivo, In Vitro and In Silico (Graphical Representation included)
- D5. Rest of Asia-Pacific
- Rest of Asia-Pacific Market Analysis
- Analysis by Geographic Region
- Exhibit 139: ADME/Tox Technologies (2005-2012) - Rest of
Asia-Pacific Market Analysis (Current & Future) by Geographic Region for
South Korea, Singapore, Hong Kong and Other in US$ Million (Graphical
Representation included)
- Exhibit 140: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Rest of Asia-Pacific Market Value by Geographic
Region South Korea, Singapore, Hong Kong and Other (Graphical
Representation included)
- Analysis by Technology
- Exhibit 141: ADME/Tox Technologies (2005-2012) - Rest of
Asia-Pacific Market Analysis (Current & Future) by Predictive Technology
for In Vivo, In Vitro and In Silico in US$ Million (Graphical
Representation included)
- Exhibit 142: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Rest of Asia-Pacific Market Value by Predictive
Technology for In Vivo, In Vitro and In Silico (Graphical Representation
included)
- E. Rest of World
- Latin America
- Middle East
- Africa
- Exhibit 143: List of Major Companies in Rest of World
- Rest of World Market Analysis
- Exhibit 144: ADME/Tox Technologies (2005-2012) - Rest of World
Market Analysis (Current & Future) by Predictive Technology for In Vivo,
In Vitro and In Silico in US$ Million (Graphical Representation included)
- Exhibit 145: ADME/Tox Technologies ( 2006, 2009 and 2012):
Percentage Breakdown of Rest of Asia-Pacific Market Value by Predictive
Technology for In Vivo, In Vitro and In Silico (Graphical Representation
included)
- 8. ADME/Tox Technologies - The Industry Outlook
V. CORPORATE DIRECTORY
|
|
|
|
|
|
|
[Report]
ADME /TOX TECHNOLOGIES - A MARKET INSIGHT REPORT
Published: 2008/01
|
Published by : RI Technologies  |
|
|
Price:
|
Product Code : RIT63056 |
|
|
Please inform me when related publications are released
|
|
|
View Cart
